People in the study receive ifinatamab deruxtecan over time during regular treatment visits. The study is open-label, which means both the study team and the participant know which treatment is being given. The course of the study includes treatment and follow-up visits to watch for side effects and to see how long any benefit lasts. The study also looks at how long people live without the cancer getting worse and how many side effects happen during treatment.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

The purpose of the study is to see if Ifinatamab deruxtecan can help people with advanced or metastatic ESCC live longer compared to the other chemotherapy treatments. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of up to 54 weeks, during which participants will be closely monitored by healthcare professionals. The study will also look at how the treatment affects the quality of life and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and imaging tests like computed tomography (CT) or magnetic resonance imaging (MRI) to track the progress of the disease. The study aims to provide valuable information on the effectiveness and safety of Ifinatamab deruxtecan for treating ESCC, potentially offering a new option for patients with this challenging condition.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

The purpose of this study is to evaluate the safety and effectiveness of Tislelizumab in treating elderly patients with advanced esophageal squamous cell carcinoma who cannot receive standard chemotherapy. Participants in the study will receive Tislelizumab and will be monitored over a period of time to see how well they respond to the treatment. The study aims to assess how many patients are still alive six months after starting the treatment and to gather information on their overall health and quality of life during this period.

Throughout the study, researchers will also look at various factors such as the safety of the treatment, the overall survival of patients, and how the cancer responds to the medication. The study will also consider the expression of a protein called PD-L1, which may influence how well the treatment works. Additionally, the study will evaluate the quality of life of the patients and other health-related factors to provide a comprehensive understanding of the treatment’s impact.

The purpose of the study is to evaluate the safety and tolerability of these treatment combinations and to determine the best dose for the new drug. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor how well the treatments work and how the body responds to them over time. This includes looking at how long the treatment effects last, how the disease progresses, and overall survival rates.

Throughout the study, researchers will also measure the levels of Ifinatamab Deruxtecan in the blood to understand how the drug is processed by the body. The study aims to provide valuable information on the effectiveness and safety of these treatment combinations for people with advanced esophageal cancer.

The purpose of the study is to evaluate how well these treatments work in preventing the cancer from getting worse and in improving the overall survival of patients. Participants in the study will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 51 weeks, during which participants will be closely monitored by healthcare professionals. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo, to ensure unbiased results.

Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of their cancer. The main goal is to see if the combination of Atezolizumab and Tiragolumab can help patients live longer and keep their cancer from progressing compared to those receiving the placebo. This study is an important step in finding more effective treatments for people with this type of esophageal cancer.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

The purpose of the study is to see how well Durvalumab works when used with chemoradiation therapy in treating this type of cancer. Participants in the study will receive either Durvalumab or a placebo, along with chemoradiation therapy. The study will monitor the participants over a period to observe the effects of the treatment on their cancer. The study will also collect information on how the treatment affects the participants’ quality of life and any side effects they may experience.

Other medications involved in the study include Fluorouracil, Cisplatin, and Capecitabine, which are types of chemotherapy drugs, as well as Infliximab and Mycophenolate Mofetil, which are used to manage immune responses. These medications are administered in different forms, such as injections, infusions, or tablets, depending on the specific treatment plan. The study aims to provide valuable information on the effectiveness and safety of using Durvalumab in combination with these treatments for patients with this type of esophageal cancer.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to see if combining Bintrafusp alfa with standard cancer treatments like chemotherapy and radiation is feasible for patients with this type of cancer. Chemotherapy involves using drugs like carboplatin and paclitaxel to kill cancer cells, while radiation uses high-energy rays to target and destroy cancer cells. The study will observe how well patients can complete the treatment plan, which includes at least two out of three planned cycles of Bintrafusp alfa.

Participants in the study will receive the treatment over a period of time and will be monitored for any side effects or changes in their condition. The study will also look at various outcomes, such as the safety of the treatment, how well the cancer responds, and the overall quality of life for the patients. This includes looking at symptoms like difficulty swallowing, which is common in esophageal cancer. The study aims to gather information that could help improve treatment options for people with this type of cancer in the future.

The purpose of this study is to evaluate the safety and tolerability of these combination treatments and to estimate how well they work in treating the cancer. Participants in the study will receive these treatments and be monitored for any side effects or improvements in their condition. The study will be conducted in phases, starting with a safety lead-in phase to ensure the treatments are safe for participants. Following this, the study will assess how well the treatments work in controlling the cancer.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on the potential benefits and risks of these new treatment combinations for people with advanced esophageal cancer. The results will help determine if these treatments can be used more widely in the future to improve outcomes for patients with this type of cancer.

The medications used in this study include Fluorouracil, Cisplatin, Carboplatin, Paclitaxel, Folinic Acid (also known as Leucovorin), and Oxaliplatin. These drugs are administered through an intravenous infusion, which means they are given directly into a vein. The study will monitor patients over a period of time to assess their overall survival, quality of life, and any side effects from the treatments.

Participants in the study will receive one of the two treatment plans and will be followed for several years to track their health outcomes. The study aims to provide valuable information on the effectiveness and safety of these treatment strategies for patients with operable, locally advanced esophageal squamous cell carcinoma.

The purpose of the study is to see if taking budesonide for eight weeks can help prevent the formation of esophageal strictures in adults who have undergone the endoscopic procedure. Participants in the study will be randomly assigned to receive either a low dose or a high dose of budesonide, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will take the medication or placebo for a total of eight weeks. The main goal is to determine how many participants remain free of esophageal strictures by the end of the study period. Additionally, the study will track the number of times participants need a procedure called endoscopic dilation, which is used to widen the esophagus if strictures do occur. The results will help determine if budesonide is an effective treatment for preventing esophageal strictures after endoscopic submucosal dissection.